CD47 and neoplasm: All three treatment groups, except for PBS, exhibited reduced tumor burden to varying degrees, the C + o treatment group demonstrated superior tumor regression and survival benefits compared to oAd-CD47 group and CAR-Ms group in the CT26 tumor model (Fig. 5A, B).